

Special Issue

Genetics and Epigenetics in Cardiovascular Disease

Message from the Guest Editors

Genetics and epigenetics play a crucial role in the development and progression of cardiovascular diseases (CVDs). The aim of this Special Issue is to highlight and explore the genetic and epigenetic factors involved in CVDs, to drive advancements in personalized medicine, and to offer tailored approaches to diagnosis, risk assessment, and treatment. The scope of this Special Issue includes, but is not limited to, the following topics: Understanding the intricate interplay between exercise, nutrition, and epigenetic regulation to elucidate the underlying mechanisms of CVD prevention.

Pharmacogenomic studies to identify the genetic variants associated with differential responses to drugs commonly used in the treatment of CVD.

Identification of genetic and epigenetic biomarkers playing a pivotal role in the development of risk prediction models for cardiovascular diseases.

Understanding the intricate interplay between the gut microbiome, diet, and host epigenome in cardiovascular disease to offer insights into potential therapeutic strategies.

Guest Editors

Dr. Cristina Mazzaccara
Prof. Dr. Carmela Nardelli
Prof. Dr. Giulia Frisso

Deadline for manuscript submissions

closed (15 October 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/201754

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2
(Genetics (clinical))